MT101-5
/ Mthera Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 25, 2024
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd. | Trial primary completion date: Dec 2024 ➔ Jul 2025
Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
March 15, 2024
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd. | Initiation date: Jan 2024 ➔ Jul 2024
Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease
December 19, 2023
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Mthera Pharma Co., Ltd.
New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 3
Of
3
Go to page
1